6.
Yao C, Su L, Shan J, Zhu C, Liu L, Liu C
. IGF/STAT3/NANOG/Slug Signaling Axis Simultaneously Controls Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer. Stem Cells. 2016; 34(4):820-31.
DOI: 10.1002/stem.2320.
View
7.
Flint T, Janowitz T, Connell C, Roberts E, Denton A, Coll A
. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab. 2016; 24(5):672-684.
PMC: 5106372.
DOI: 10.1016/j.cmet.2016.10.010.
View
8.
Ene-Obong A, Clear A, Watt J, Wang J, Fatah R, Riches J
. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013; 145(5):1121-32.
PMC: 3896919.
DOI: 10.1053/j.gastro.2013.07.025.
View
9.
Alemi Yahya M, Meisel Sharon S, Hantisteanu S, Hallak M, Werner H, Bruchim I
. [THE PROLIFERATIVE EFFECT OF DENDRITIC CELLS IN OVARIAN CANCER AND THE RELATIONSHIP WITH THE IGF SIGNALING PATHWAY]. Harefuah. 2019; 158(1):30-34.
View
10.
Boutilier A, Elsawa S
. Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021; 22(13).
PMC: 8268869.
DOI: 10.3390/ijms22136995.
View
11.
Krause C, He W, Kotenko S, Pestka S
. Modulation of the activation of Stat1 by the interferon-gamma receptor complex. Cell Res. 2006; 16(1):113-23.
DOI: 10.1038/sj.cr.7310015.
View
12.
Uzunparmak B, Sahin I
. Pancreatic cancer microenvironment: a current dilemma. Clin Transl Med. 2019; 8(1):2.
PMC: 6333596.
DOI: 10.1186/s40169-019-0221-1.
View
13.
Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D
. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212-7.
PMC: 3864274.
DOI: 10.1073/pnas.1320318110.
View
14.
Zboralski D, Hoehlig K, Eulberg D, Fromming A, Vater A
. Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade. Cancer Immunol Res. 2017; 5(11):950-956.
DOI: 10.1158/2326-6066.CIR-16-0303.
View
15.
Mace T, Shakya R, Pitarresi J, Swanson B, McQuinn C, Loftus S
. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2016; 67(2):320-332.
PMC: 5406266.
DOI: 10.1136/gutjnl-2016-311585.
View
16.
Lv J, Liu C, Chen F, Feng Z, Jia L, Liu P
. M2‑like tumour‑associated macrophage‑secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway. Mol Med Rep. 2021; 24(2).
PMC: 8258465.
DOI: 10.3892/mmr.2021.12249.
View
17.
Peng D, Rodriguez B, Diao L, Chen L, Wang J, Byers L
. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8 T cell exhaustion. Nat Commun. 2020; 11(1):4520.
PMC: 7481212.
DOI: 10.1038/s41467-020-18298-8.
View
18.
Nywening T, Wang-Gillam A, Sanford D, Belt B, Panni R, Cusworth B
. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016; 17(5):651-62.
PMC: 5407285.
DOI: 10.1016/S1470-2045(16)00078-4.
View
19.
Litchfield K, Reading J, Puttick C, Thakkar K, Abbosh C, Bentham R
. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021; 184(3):596-614.e14.
PMC: 7933824.
DOI: 10.1016/j.cell.2021.01.002.
View
20.
Gorchs L, Moro C, Bankhead P, Kern K, Sadeak I, Meng Q
. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4 and CD8 T-Cells. Front Immunol. 2019; 10:847.
PMC: 6491453.
DOI: 10.3389/fimmu.2019.00847.
View